Transplantation for Patients With Chronic Lymphocytic Leukemia

Not Applicable

Completed

• Conditions: Leukemia, Lymphocytic, Chronic

• Registration Number: NCT00186303
• Lead Sponsor: Stanford University

Brief Summary

To evaluate the role of high dose therapy and autologous or allogeneic hematopoietic cell transplantation for the treatment of chronic lymphocytic leukemia.

Detailed Description

To determine effectiveness of allogeneic transplantation in eradicating chronic lymphocytic leukemia.

Study Timeline

• Study Start: 1996-11
• Study First Submitted: 2005-09-13
• Study First Submitted QC: 2005-09-13
• Study First Posted: 2005-09-16
• Primary Completion: 2010-03
• Study Completion: 2010-03
• Status Verified: 2012-12
• Last Update Submitted: 2012-12-13
• Last Update Posted: 2012-12-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

• adequate organ function

• normal bone marrow cytogenetics

Exclusion Criteria

• active CNS disease

• For autologous patients more than 30% bone marrow involvement

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Efficacy

Secondary Outcome Measures

Name	Time	Method
Feasibility
Toxicity
olymerase Chain Reaction (PCR) for minimal residual disease

Trial Locations

Locations (1)

Stanford University School of Medicine; 🇺🇸 Stanford, California, United States